other · Figshare
Abstract Obesity and smoking are major global health threats with synergistic impacts on metabolic disease. The combined effects of these factors on the oral-gut (Orointestinal) microbiome axis, a crucial interface for systemic immunity and metabolism, remain poorly characterized. In this cross-sectional study, 108 age- and sex-matched participants were stratified into four groups (n = 27/group): Non-Obese Non-Smokers (Control), Obese Non-Smokers, Non-Obese Smokers, and Obese-Smokers. Orointestinal microbiomes were profiled via 16 S rRNA sequencing of stool and oral rinse samples, followed by comprehensive bioinformatics analysis. Compartment-specific patterns existed in relation to smoking and obesity. The oral microbiome of Obese-Smokers exhibited a significant, dose-dependent reduction in diversity (34% loss at > 20 cigarettes/day; padj = 0.008), synergistic depletion of oral commensals such as Elizabethkingia (log2FC = − 6.33, padj = 0.0032) and enrichment of pathobionts such as Escherichia_Shigella (log2FC = 3.2, padj = 0.00068). In contrast, the gut microbiome maintained stable bacterial diversity across groups, despite profound compositional shifts (PERMANOVA, padj = 0.003), with smokers showing a significantly elevated Firmicutes/Bacteroidetes ratio (1.78 vs. 0.91 in controls; padj = 0.006). Critically, Obese-Smokers revealed a significant bidirectional pattern of the Orointestinal axis, specifically in the oral cavity, as evidenced by the significant Orointestinal co-occurrence of the oral pathobionts Neisseria and Leptotrichia (r = 0.67, p = 0.0001), which potentially highlights microbial covariation across habitats. A random forest model identified the oral taxon F0058 (Saccharimonadaceae) as a potential biomarker for Obese-Smoker status (AUC = 0.975, padj = 0.017). Obesity and smoking are associated with synergistic orointestinal dysbiosis, pathobiont expansion, commensal loss, and potential microbial covariation across habitats. The vulnerable oral microbiome, specifically the F0058 biomarker, offers a promising target for noninvasive risk stratification and intervention.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.6084/m9.figshare.c.8425852.v1
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.